CN103446165A - Application of guluronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury - Google Patents
Application of guluronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury Download PDFInfo
- Publication number
- CN103446165A CN103446165A CN2013104151542A CN201310415154A CN103446165A CN 103446165 A CN103446165 A CN 103446165A CN 2013104151542 A CN2013104151542 A CN 2013104151542A CN 201310415154 A CN201310415154 A CN 201310415154A CN 103446165 A CN103446165 A CN 103446165A
- Authority
- CN
- China
- Prior art keywords
- oligoguluronic acid
- application
- oligoguluronic
- liver injury
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides application of guluronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury. Guluronic acid oligomers with different molecular weights, which are obtained by degrading polyguluronic acid graded and purified from algin, can lower the hepatosomatic index increase caused by alcoholic injury, resist triglyceride and cholesterol increase caused by alcohol, effectively lower glutamic-pyruvic transaminase and glutamic oxaloacetic transaminase increase in serum caused by alcohol, enhance the total oxidation resistance, glutathione level and superoxide dismutase activity in the serum, inhibit the generation of malonaldehyde in the liver caused by alcohol, lower the mouse drunkenness rate, prolong the mouse drunkenness time, and shorten the sober-up time, thereby implementing the protective action and hangover alleviating function on alcoholic hepatic injury. The products provided by the invention are derived from marine natural products, have the advantages of abundant resources, high industrialization tendency, high safety, high effectiveness and the like, and have wide development and application prospects in the aspects of prevention and treatment of alcoholic hepatic injury, hangover alleviation and liver protection.
Description
Technical field
The invention belongs to the marine drug field, be specifically related to the application of oligoguluronic acid in medicine, health product or the dietary supplement of preparation prevention and treatment alcoholic liver injury.
Background technology
The hepar damnification that excessive consumption of alcohol causes is a worldwide difficult medical problem.Alcoholic fatty liver (ALD) is the Early manifestation of hepatic injury due to ethanol, and then can develop into alcoholic hepatitis, hepatic fibrosis, liver cirrhosis or even hepatocarcinoma.In developed countries such as America and Europes, alcoholic liver disease and complication thereof are to cause one of dead Important cause of disease.In recent years, China ALD also presents the situation such as sickness rate increases year by year, the liver injury degree increases the weight of, impaired Functional tissue increases, and oneself causes systematicness harm to population of China health.
The pathogenesis complexity of ALD, the oxidative stress produced in the alcohol metabolism process is the major reason of ALD.Oxidative stress can the lesion wire plastochondria, causes the mitochondrial function disorder.Ethanol also can cause that accumulating of homocysteine causes er stress, causes protein misfolding, and then causes accumulation of lipid, inflammatory reaction and apoptosis.
At present, for the ALD treatment, except alleviating alcohol addiction and nutritional support, take Drug therapy as main clinically, as improved silymarin, the glutathion of body antioxygen power; The glucocorticoid of inflammation-inhibiting reaction; The medicines such as the metadoxine of adjusting liver function, polyene phosphatidylcholine.Yet the application of these medicines all has certain limitation, can not well meet clinical demand.Therefore, exploitation safely and effectively, can prevent the medicine of ALD to have great importance.
Oligoguluronic acid is a kind of intercellular polysaccharide that separates acquisition that extracts in the Brown algae of ocean, is the line style compound connected to form by α-Isosorbide-5-Nitrae-glycosidic bond by L-guluronic acid (guluronic acid, G).At present, there is the bibliographical information oligoguluronic acid to there is the various biological activity such as antioxidation, immunomodulating, adjusting mucosa protein function both at home and abroad, but there is not yet the report that is applied to the alcoholic liver injury aspect.The present invention adopts animal acute alcohol liver injury model; the impact of the effect that the triglyceride that the oligoguluronic acid of exploration different polymerization degree causes ethanol, cholesterol raise; and investigated oligoguluronic acid solution antagonism Alcoholic Oxidation, find that oligoguluronic acid has significant protective effect in the animal level to alcoholic liver injury.The plurality of advantages such as rule of origin Yu Haiyang natural product of the present invention, have aboundresources, be easy to industrialization, safe and effective, have wide development prospect aspect control alcoholic liver injury, relieving alcoholism and protecting the liver.
Summary of the invention
The purpose of this invention is to provide the application of oligoguluronic acid in medicine, health product or the dietary supplement of preparation prevention and treatment alcoholic liver injury, utilize oligoguluronic acid for prevention and treat alcoholic fatty liver, relieving alcoholism and protecting the liver.
For achieving the above object, the present invention adopts following technical proposals to be achieved:
The application of oligoguluronic acid in medicine, health product or the dietary supplement of preparation prevention and treatment alcoholic liver injury.
It is raw material that described oligoguluronic acid be take alginic acid or sodium alginate, through chemistry or the degraded of mechanical degradation method, prepare, its molecular skeleton is that L-guluronic acid G is by α-(1,4) ol cpds that-glycosidic bond is connected to form, weight average molecular weight range is 3kD-13kD, and general structure is as follows:
R=H or Na in formula, Li, Ca, the Mg pharmaceutical salts, n is 1-60.
Further, described chemical degradation method is acid degradation or Fenton edman degradation Edman.
Further, described mechanical degradation method is degradation of xylan with microwave.
Described oligoguluronic acid can reduce the liver Body Mass Index rising caused by alcohol damaged.
Described oligoguluronic acid can reduce Triglycerides in Serum, cholesterol levels, and reduces glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT level in the serum that ethanol causes.
Described oligoguluronic acid can improve serum antioxidative activities, glutathione level and superoxide dismutase activity, thus the oxidative damage that antagonism ethanol causes.
Described oligoguluronic acid can reduce mda content in liver, suppresses the oxidative stress that ethanol causes.
Described oligoguluronic acid can reduce the mice drunk rate, extends the mice drunk time, shortens the mice relieving alcoholic intoxication time, thereby reaches the effect of Antialcoholic liver-protecting.
Compared with prior art; advantage of the present invention and technique effect are: the present invention adopts kunming mice acute alcohol liver injury model; by disposable give with excessive alcohol before 2h; give oligoguluronic acid protected according to weight ratio, explore the protective effect of oligoguluronic acid to alcoholic liver injury.Prove that by experiment oligoguluronic acid can reduce the liver body index rising caused by alcohol damaged; the triglyceride that antagonism ethanol causes (TG), cholesterol (TC) raise; effectively reduce ALT and AST rising that ethanol causes; improve GSH level, SOD vigor and serum antioxidative activities in serum; reduce MDA content in hepatic tissue; by the performance antioxidation, realize the protective effect to alcoholic liver injury.
The plurality of advantages such as rule of origin Yu Haiyang natural product of the present invention, have aboundresources, be easy to industrialization, safe and effective, have wide development prospect aspect the control alcoholic liver injury.
The specific embodiment
Below in conjunction with the specific embodiment, technical scheme of the present invention is described in further detail.
Embodiment 1: the preparation of different molecular weight oligoguluronic acid
Guluronic acid (Mw=12.6kD, i.e. G-12K) is configured to the suspension of variable concentrations with pure water, ultrasonic 1min, dissolve fully it.It is added to (every tank 25mL) in 8 microwave extracting tanks, it is 800W that power is set, and microwave degradation different time (reaction condition is in Table 1) under different temperature conditions, after products therefrom is cooling, double-deck filter paper filtering, lyophilizing, obtain the guluronic acid oligosaccharide mixture, and lyophilization can obtain the oligoguluronic acid of different molecular weight, be G-3K, G-4K, G-5K, G-6K.
The structural formula of the described oligoguluronic acid made is as follows: R=H or Na in formula, Li, Ca, the pharmaceutical salts such as Mg.
In formula, n is 1-60
As standard, record the weight average molecular weight of the oligoguluronic acid of acquisition with TOSOH TSK GEL3000PWXL column chromatography (7.8mm*300mm, 6 μ m) and dextran standard substance (Nat'l Pharmaceutical & Biological Products Control Institute).
Weight average molecular weight and the breadth coefficient of the oligoguluronic acid prepared according to the present invention are as shown in table 1.
Relation between table 1 sample concentration, reaction temperature, time and oligoguluronic acid weight average molecular weight
Embodiment 2: the inhibitory action that the mouse liver Body Mass Index that oligoguluronic acid is induced ethanol raises
84 of 18-22g Kunming mouses, be divided into matched group, model group, administration group (different weight average molecular weight oligoguluronic acids, Mw=3kD, Mw=4kD, Mw=5kD, Mw=6kD, Mw=12kD), 12 every group at random.Adaptability is fed 5 days, experimental session mice ad lib normal diet and drinking-water, and single administration 200mg/kg, the disposable ethanol 4.8g/kg that gives after 2h, water is can't help in fasting.After 16h, mice is put to death, separates liver, with PBS(0.1M, the pH=7 of pre-cooling) solution rinsing twice, then with filter paper, the moisture of organ surface is blotted, weigh, calculate organ index.Computing formula is as follows: organ index (%)=organ weights (g)/body weight (g) * 100%, result is as shown in table 2.
The inhibitory action that table 2 different molecular weight oligoguluronic acid raises to liver index due to ethanol
##P<0.01, compare with Normal group; * P<0.05, * * P<0.01, compare with model group; (n=12; X ± SD)
Table 2 test result shows, the oligoguluronic acid oral administration of different molecular weight all can obviously suppress the mouse liver Body Mass Index that ethanol causes and raise.
Embodiment 3: the inhibitory action that the mice serum TG that oligoguluronic acid is induced ethanol, TC level raise
60 of 18-22g Kunming mouses, be divided into matched group, model group, administration group (different weight average molecular weight oligoguluronic acids, Mw=3kD, M-5kD, Mw=12kD), 12 every group at random.Adaptability is fed 5 days, experimental session mice ad lib normal diet and drinking-water, and single administration 200mg/kg, the disposable ethanol 4.8g/kg that gives after 2h, water is can't help in fasting, and after 16h, eyeball is got blood, and 3000rpm * 10min prepares serum, measures TG, TC index.As shown in table 3.
The inhibitory action that table 3 different molecular weight oligoguluronic acid raises to TC, TG due to ethanol
##P<0.01, compare with Normal group; * P<0.05, * * P<0.01, compare with model group; (n=12; X ± SD)
Table 3 test result shows, the oligoguluronic acid oral administration of different molecular weight all can obviously suppress the rising of cholesterol (TC) level in mice serum that ethanol causes.The oligoguluronic acid of different molecular weight also can suppress the rising of triglyceride (TG) level in mice serum that ethanol causes, and suppresses active and strengthen along with the reduction of molecular weight.Be that result shows that oligoguluronic acid can alleviate because of the lipopexia due to drinking.
Embodiment 4: the inhibitory action that the mice serum ALT that oligoguluronic acid is induced ethanol, AST level raise
60 of 18-22g Kunming mouses, be divided into matched group, model group, administration group (different weight average molecular weight oligoguluronic acids, Mw=3kD, Mw=5kD, Mw=12kD), 12 every group at random.Adaptability is fed 3-5 days, experimental session mice ad lib normal diet and drinking-water, single administration 200mg/kg, the disposable ethanol 4.8g/kg that gives after 2h, water is can't help in fasting, and after 16h, eyeball is got blood, 3000rpm * 10min prepares serum, measures ALT, AST index, and experimental result is as shown in table 4.
Table 4 different molecular weight oligoguluronic acid is to ALT, AST level raise due to ethanol inhibitory action
##P<0.01, compare with Normal group; * P<0.05, * * P<0.01, compare with model group; (n=12; X ± SD)
Table 4 test result shows, the oligoguluronic acid oral administration of different molecular weight all can obviously suppress the rising of glutamate pyruvate transaminase (ALT), glutamic oxaloacetic transaminase, GOT (AST) level in mice serum that ethanol causes.Show that guluronic acid can protect hepatocyte, alleviate inflammatory reaction.
Embodiment 5: oligoguluronic acid improves mice serum total antioxidant capacity and superoxide dismutase activity, and rising serum GSH-PX activity level
60 of 18-22g Kunming mouses, be divided at random matched group, model group, administration group (weight average molecular weight Mw=3kD oligoguluronic acid, high dose group G-3K-H:200mg/kg, middle dosage group G-3K-M:100mg/kg, low dose group G-3K-L:50mg/kg), 12 every group.Adaptability is fed 3-5 days, experimental session mice ad lib normal diet and drinking-water, and the disposable ethanol 4.8g/kg that gives after administration 2h, water is can't help in fasting, and after 6h, eyeball is got blood, and 3000rpm * 10min prepares serum, measures T-AOC, SOD and GSH index in serum.Experimental result is as shown in table 5.
Table 5 oligoguluronic acid is to antagonism that in serum due to ethanol, T-AOC, GSH level and SOD vigor reduce
#P<0.05, compare with Normal group; * P<0.05, * * P<0.01, compare with model group; (n=12; X ± SD).
Table 5 test result shows, the oligoguluronic acid oral administration of different molecular weight all can obviously improve serum total antioxidant capacity (T-AOC) and superoxide dismutase (SOD) vigor, the decline of mice serum GSH-PX activity (GSH) level that antagonism ethanol causes, and there is dose dependent.
Embodiment 6: the inhibitory action that oligoguluronic acid is synthetic to malonaldehyde in hepatic tissue
60 of 18-22g Kunming mouses, be divided at random matched group, model group, administration group (weight average molecular weight Mw=3kD oligoguluronic acid, high dose group G-3K-H:200mg/kg, middle dosage group G-3K-M:100mg/kg, low dose group G-3K-L:50mg/kg), 12 every group.Adaptability is fed 5 days, experimental session mice ad lib normal diet and drinking-water, and the disposable ethanol 4.8g/kg that gives after administration 2h, water is can't help in fasting, gets murine liver tissue after 6h, prepares 10% liver tissue homogenate's liquid, measures MDA content in liver.Experimental result is as shown in table 6.
The inhibitory action that table 6 oligoguluronic acid is synthetic to MDA in hepatic tissue
#P<0.05, compare with Normal group; * P<0.05, * * P<0.01, compare with model group; (n=12; X ± SD).
Table 6 test result shows, the oligoguluronic acid oral administration of different molecular weight all can obviously reduce malonaldehyde in liver (MDA) content, and has dose dependent.
Embodiment 7: the experiment of mice drunk relieving alcoholic intoxication
50 of 18-22g Kunming mouses, be divided at random matched group, model group, high, medium and low dosage group (the weight average molecular weight Mw=3kD oligoguluronic acid of administration, high dose group G-3K-H:200mg/kg, middle dosage group G-3K-M:100mg/kg, low dose group G-3K-L:50mg/kg), 10 every group.Adaptability is fed 5 days, experimental session mice ad lib normal diet and drinking-water, the disposable ethanol 5.4g/kg that gives after administration 2h, observe mice upset areflexia, be drunk.Add up drunk mice number of elements, calculate drunk rate: drunk rate=drunk mice number of elements/experiment mice number of elements * 100%.Be the drunk time from giving mice ethanol to time of mice upset areflexia, the time of recovering the upset reflection after mice drunk is the relieving alcoholic intoxication time.Mice drunk judgement: mice is got and puts into dorsad cage, if mice dorsad more than lower posture maintenance 30s, is thought and is the upset areflexia drunk.Experimental result is as shown in table 7.
The experiment of table 7 mice drunk relieving alcoholic intoxication
Table 7 experimental result shows that oligoguluronic acid can reduce the mice drunk rate in the experiment of chmice acute alcoholic hepatic injury, extends the drunk time, shortens the relieving alcoholic intoxication time, thereby reaches the purpose of Dealcoholic sobering-up.Comprehensive other testing index interpretations of result, oligoguluronic acid can reduce the mouse liver Body Mass Index, suppresses the rising of TG, TC level in serum due to ethanol, and the rising of serum alt, AST level, have the relieving alcoholism and protecting the liver effect due to antagonism ethanol.
Oligoguluronic acid can improve T-AOC content in mice serum, SOD vigor and GSH level; simultaneously; can suppress the generation of MDA in liver; thereby can activate the antioxidant system of body; suppress to a certain extent oxidative stress due to ethanol, realize the protective effect to the acute alcohol liver damage.
Because alcoholic fatty liver due to ethanol is the initial performance of hepar damnification, it is remarkable and the most important investigation index that TG raises, simultaneously, comprehensive other experimental results, in the present invention, the Antialcoholic liver-protecting effect of low-molecular-weight oligoguluronic acid is more remarkable, has the potential quality that exploitation becomes the health product of control alcoholic liver injury.
Above embodiment is only in order to technical scheme of the present invention to be described, but not is limited; Although with reference to previous embodiment, the present invention is had been described in detail, for the person of ordinary skill of the art, the technical scheme that still can put down in writing previous embodiment is modified, or part technical characterictic wherein is equal to replacement; And these modifications or replacement do not make the essence of appropriate technical solution break away from the spirit and scope of the present invention's technical scheme required for protection.
Claims (9)
1. the application of oligoguluronic acid in medicine, health product or the dietary supplement of preparation prevention and treatment alcoholic liver injury.
2. the application of oligoguluronic acid according to claim 1 in medicine, health product or the dietary supplement of preparation prevention and treatment alcoholic liver injury, it is characterized in that: it is raw material that described oligoguluronic acid be take alginic acid or sodium alginate, through chemistry or the degraded of mechanical degradation method, prepare, its molecular skeleton is that L-guluronic acid G is by α-(1,4) ol cpds that-glycosidic bond is connected to form, weight average molecular weight range is 3kD-13kD, and general structure is as follows:
R=H or Na in formula, Li, Ca, the Mg pharmaceutical salts, n is 1-60.
3. the application of oligoguluronic acid according to claim 2 in medicine, health product or the dietary supplement of preparation prevention and treatment alcoholic liver injury, it is characterized in that: described chemical degradation method is acid degradation or Fenton edman degradation Edman.
4. the application of oligoguluronic acid according to claim 2 in medicine, health product or the dietary supplement of preparation prevention and treatment alcoholic liver injury, it is characterized in that: described mechanical degradation method is degradation of xylan with microwave.
5. the application of oligoguluronic acid according to claim 1 and 2 in medicine, health product or the dietary supplement of preparation prevention and treatment alcoholic liver injury is characterized in that: described oligoguluronic acid can reduce the liver Body Mass Index rising caused by alcohol damaged.
6. the application of oligoguluronic acid according to claim 1 and 2 in medicine, health product or the dietary supplement of preparation prevention and treatment alcoholic liver injury, it is characterized in that: described oligoguluronic acid can reduce Triglycerides in Serum, cholesterol levels, and reduces glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT level in the serum that ethanol causes.
7. the application of oligoguluronic acid according to claim 1 and 2 in medicine, health product or the dietary supplement of preparation prevention and treatment alcoholic liver injury, it is characterized in that: described oligoguluronic acid can improve serum antioxidative activities, glutathione level and superoxide dismutase activity, thus the oxidative damage that antagonism ethanol causes.
8. the application of oligoguluronic acid according to claim 1 and 2 in medicine, health product or the dietary supplement of preparation prevention and treatment alcoholic liver injury, it is characterized in that: described oligoguluronic acid can reduce mda content in liver, suppresses the oxidative stress that ethanol causes.
9. the application of oligoguluronic acid according to claim 1 and 2 in medicine, health product or the dietary supplement of preparation prevention and treatment alcoholic liver injury, it is characterized in that: described oligoguluronic acid can reduce the mice drunk rate, extend the mice drunk time, shorten the mice relieving alcoholic intoxication time, thereby reach the effect of Antialcoholic liver-protecting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310415154.2A CN103446165B (en) | 2013-09-12 | 2013-09-12 | Oligoguluronic acid is preparing the application in the medicine of prevention and therapy alcoholic liver injury, health product or dietary supplement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310415154.2A CN103446165B (en) | 2013-09-12 | 2013-09-12 | Oligoguluronic acid is preparing the application in the medicine of prevention and therapy alcoholic liver injury, health product or dietary supplement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103446165A true CN103446165A (en) | 2013-12-18 |
| CN103446165B CN103446165B (en) | 2016-04-13 |
Family
ID=49729286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310415154.2A Expired - Fee Related CN103446165B (en) | 2013-09-12 | 2013-09-12 | Oligoguluronic acid is preparing the application in the medicine of prevention and therapy alcoholic liver injury, health product or dietary supplement |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103446165B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103977021A (en) * | 2014-03-25 | 2014-08-13 | 青岛海洋生物医药研究院股份有限公司 | Application of oligoguluronates in preparation of drugs for prevention and treatment of liver damage and various hepatitis, liver fibrosis or cirrhosis |
| CN104083395A (en) * | 2014-06-05 | 2014-10-08 | 深圳大学 | Application of marine-derived oligoguluronic acid |
| CN105395563A (en) * | 2015-12-11 | 2016-03-16 | 青岛海洋生物医药研究院股份有限公司 | Application of oligoguluronic acid and derivative thereof in preparation of drugs and health products used for preventing and treating hyperlipidemia and complications thereof |
| CN107823635A (en) * | 2017-11-29 | 2018-03-23 | 杭州睿道医药科技有限公司 | The application of manganese type high stability superoxide dismutase |
| CN114533774A (en) * | 2022-03-16 | 2022-05-27 | 长三角健康农业研究院(浙江)有限公司 | Natural compound for dispelling effects of alcohol and protecting liver and preparation process thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1341602A (en) * | 2000-09-07 | 2002-03-27 | 青岛海洋大学 | Preparation method of guluronic acid with single degree of polymerization and its application |
| CN1544446A (en) * | 2003-11-22 | 2004-11-10 | 中国海洋大学 | Guluronicacid oligosaccharides production method utilizing Fenton-type reaction |
| CN101011411A (en) * | 2006-12-08 | 2007-08-08 | 北京世纪博康医药科技有限公司 | Usage of algal polysaccharide sulfate in preparation of medicament for treating hepatic disease |
| WO2009069131A1 (en) * | 2007-11-27 | 2009-06-04 | Hadasit Medical Research Services & Development Ltd. | Alginate biomaterials for the treatment of hepatic disorders |
-
2013
- 2013-09-12 CN CN201310415154.2A patent/CN103446165B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1341602A (en) * | 2000-09-07 | 2002-03-27 | 青岛海洋大学 | Preparation method of guluronic acid with single degree of polymerization and its application |
| CN1544446A (en) * | 2003-11-22 | 2004-11-10 | 中国海洋大学 | Guluronicacid oligosaccharides production method utilizing Fenton-type reaction |
| CN101011411A (en) * | 2006-12-08 | 2007-08-08 | 北京世纪博康医药科技有限公司 | Usage of algal polysaccharide sulfate in preparation of medicament for treating hepatic disease |
| WO2009069131A1 (en) * | 2007-11-27 | 2009-06-04 | Hadasit Medical Research Services & Development Ltd. | Alginate biomaterials for the treatment of hepatic disorders |
Non-Patent Citations (3)
| Title |
|---|
| 杜时雨等: "脂质过氧化反应在大鼠急性酒精性肝损害中的作用", 《胃肠病学和肝病学杂志》, vol. 17, no. 07, 20 July 2008 (2008-07-20), pages 600 - 602 * |
| 王浩贤: "聚甘露糖醛酸和聚古罗糖醛酸纯化及降解产物活性研究", 《中国优秀硕士学位论文全文数据库 工程科技 I辑》, no. 02, 15 February 2013 (2013-02-15), pages 024 - 43 * |
| 王莹等: "几种寡聚古罗糖醛酸的制备和结构表征", 《高等学校化学学报》, vol. 26, no. 01, 15 January 2005 (2005-01-15), pages 179 - 183 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103977021A (en) * | 2014-03-25 | 2014-08-13 | 青岛海洋生物医药研究院股份有限公司 | Application of oligoguluronates in preparation of drugs for prevention and treatment of liver damage and various hepatitis, liver fibrosis or cirrhosis |
| CN104083395A (en) * | 2014-06-05 | 2014-10-08 | 深圳大学 | Application of marine-derived oligoguluronic acid |
| CN105395563A (en) * | 2015-12-11 | 2016-03-16 | 青岛海洋生物医药研究院股份有限公司 | Application of oligoguluronic acid and derivative thereof in preparation of drugs and health products used for preventing and treating hyperlipidemia and complications thereof |
| CN107823635A (en) * | 2017-11-29 | 2018-03-23 | 杭州睿道医药科技有限公司 | The application of manganese type high stability superoxide dismutase |
| WO2019105060A1 (en) * | 2017-11-29 | 2019-06-06 | 杭州睿道医药科技有限公司 | Use of manganese-type high-stability superoxide dismutase |
| CN114533774A (en) * | 2022-03-16 | 2022-05-27 | 长三角健康农业研究院(浙江)有限公司 | Natural compound for dispelling effects of alcohol and protecting liver and preparation process thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103446165B (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103446174B (en) | Oligomannuronic acid is preparing the application in the medicine of prevention and therapy alcoholic liver injury, health product or dietary supplement | |
| CN103446165B (en) | Oligoguluronic acid is preparing the application in the medicine of prevention and therapy alcoholic liver injury, health product or dietary supplement | |
| CN102406205B (en) | Oyster polysaccharide fruit juice beverage | |
| US20150306165A1 (en) | Plant extract composition for inhibiting adipocytes, reducing body fat, promoting weight loss and increasing lipid metabolism as well as application thereof | |
| CN106135891A (en) | A kind of health food to alcoholic liver injury with defencive function | |
| CN108420826B (en) | Application of lycium barbarum polysaccharide in preparation of medicine for treating or relieving depression and pharmaceutical composition containing lycium barbarum polysaccharide | |
| CN103961365A (en) | Application of mannan-oligosaccharide aldehyde acid salt in preparing medicine for preventing and curing liver damage, various hepatitis, liver fibrosis or cirrhosis | |
| CN103977021B (en) | The application in preparation preventing and treating hepatic injury and various hepatitis, hepatic fibrosis or liver cirrhosis medicine of the oligoguluronic acid salt | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| CA3010907C (en) | Use of cistanche tubulosa extract and isoacteoside in protection of muscles | |
| Zhan et al. | Chemical constituents and pharmacological effects of durian shells in ASEAN countries: A review | |
| WO2017148414A1 (en) | Fucoidan, preparation method therefor, and uses thereof | |
| CN105395563A (en) | Application of oligoguluronic acid and derivative thereof in preparation of drugs and health products used for preventing and treating hyperlipidemia and complications thereof | |
| CN104560378A (en) | Blueberry seed oil as well as preparation method and application thereof | |
| CN103251698A (en) | Puerarin beverage with effects of dispelling alcoholism, protecting liver and protecting stomach and preparation method thereof | |
| CN1443533A (en) | Application of proanthcyanidin compound in preparation of alcoholism-relieving liver-protecting product | |
| CN101336709A (en) | Antifatigue nutrient preparation | |
| CN104666327B (en) | The application of oligomannuronic acid and its derivative in the medicine and health products for preparing antifatigue and anti-amyotrophia | |
| KR101206543B1 (en) | A composition for preventing or treating of fatty liver comprising an extract of chestnut inner shell | |
| CN109925445A (en) | Anoectochilus causes the application in acute liver drug in preparation prevention and/or treatment D-Gal | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| CN101785816B (en) | Grass-leaved sweetflag extract, medicine composition with grass-leaved sweetflag extract, preparation method and application thereof | |
| WO2008069604A1 (en) | Composition comprising the mixed herbal extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease and pain disease | |
| CN105616430B (en) | A kind of pharmaceutical composition of the treatment fatty liver containing Glucosamine | |
| CN105770565A (en) | Liver injury treating and in-vivo autioxidant enzyme activity enhancing composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160413 Termination date: 20200912 |